直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • Life Sciences
    • Transportation and Logistics
  • Experience

Biotechnology

About

Biotechnology is part of our work in Life Sciences.

Leading the way for biotechnology IP protection

Over our more than 50 years in practice, Finnegan has worked with biotech pioneers to develop and execute successful intellectual property strategies, including patenting ground-breaking advancements, enforcing patents in litigation, and defending against claims of infringement or ownership by others. We successfully represented Eli Lilly and Company in a lawsuit involving the first marketed product produced by biotechnology—human insulin—and have provided counseling or litigation services in a range of biotechnologies, such as automated DNA sequencing, the cloning of Dolly the sheep, noninvasive methods for detecting fetal aneuploidy, and platform antibody design.

Understanding the law, science, and technology

Strong IP protection has been essential to advancing the biotech industry and remains key to its continued growth. As an IP law firm comprised of scientists and biotech engineers, Finnegan is structured to stay abreast of rapid advancements in science and changing legal issues in this fast-paced, multidisciplinary industry.

As our biotechnology clients make exciting breakthroughs in ways we have yet to imagine, we help by:

  • Litigating high value products in district and appellate courts with experienced trial and appellate teams
  • Drafting and prosecuting patents for high-value products and technologies 
  • Assessing and navigating the dense patent thicket surrounding many new technologies 
  • Writing opinions and providing ongoing counseling for new and existing technologies 
  • Advocating for, and defending clients’ interests in, complex patent interferences, reexamination proceedings, and post-grant review proceedings 
  • Conducting due diligence for mergers, acquisitions, licensing, and partnering opportunities 
  • Structuring, drafting, and negotiating IP license agreements 
  • Providing trademark prosecution and counseling services

We work with clients advancing discoveries in established as well as emerging areas, including:

  • Antibody therapy 
  • Assay development
  • Cancer therapy
  • CRISPR technology
  • Gene therapy
  • Genetic engineering
  • Nanotechnology and nanobiotechnology
  • Next-generation sequencing platforms
  • Recombinant growth factors
  • Synthetic biology
  • Vaccines 

 

Everyone in this industry

Experience

Utility and design patent applications for brain machine interface company

Finnegan represents BrainCo, a developer of brain-machine interface (BMI) wearables that combine electroencephalography (EEG) signal processing with artificial intelligence (AI) and machine learning (ML) to enable users to control electronic devices using brain signals. The firm works with BrainCo to develop and implement its intellectual property strategy, including drafting and prosecuting utility and design patent applications, in support of the company’s efforts to build a robust patent portfolio covering innovations and designs related to BMI technologies used in toys, smart home appliances, and robotic devices.

Genzyme Corporation v. Sarepta Therapeutics, Inc. et al.

Representing Sarepta in defensive patent litigation involving Elevidys®, a one-time gene therapy for the treatment of a neuromuscular disease known as Duchenne muscular dystrophy (DMD) and in parallel offensive inter partes reviews (IPRs).

1:24-cv-00882, D. Del., Judge Andrews

Merck Sharp & Dohme LLC v. Hetero USA Inc., Lupin Limited et al.
Representing Merck in Hatch-Waxman litigation involving the HIV drugs ISENTRESS® and ISENTRESS® HD.

2:23-cv-00094, 2:23-cv-02364, D.N.J., Judges Cecchi, Padin, Wettre

Pioneer Hi-Bred International, Inc. et al. v. Syngenta Seeds, LLC

Representing plaintiff Pioneer in a district court patent infringement litigation involving methods for producing doubled haploid maize plants.

1:22-cv-01280, D. Del.

Bayer Cropscience LP et al. v. Corteva Agriscience LLC et al.
Representing defendant Corteva in a Delaware state court action for breach of contract arising out of a patent cross-license agreement relating to Agrobacterium-mediated plant transformation and transgenic seeds.

N22C-07-168, Delaware Superior Court, Complex Commercial Litigation Division

Corteva Agriscience LLC v. Monsanto Company et al.

Representing plaintiff Corteva Agriscience in a district court patent infringement litigation involving transgenic plants and plant cells that produce enzymes conferring herbicide resistance.

1:22-cv-01046, D. Del., Judge Williams

More

Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

European IP Blog

UPC Central Division Revokes Patent Covering Covid-19 Treatment Remdesivir

8 June 2026

Conference

BIA Start-up Festival

May 21, 2026

London

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Conference

2026 Advanced Chemical & Biotech Patent Institute

May 11-12, 2026

San Francisco

Workshop

Protecting Innovation in the Life Sciences: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law

May 7, 2026

Cambridge

More

Upcoming Events

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

News

Media Mention

Finnegan Hires Kirkland & Ellis Litigator for London Office

June 8, 2026

Commentary

Finnegan Hires Kirkland Partner as It Eyes UK Growth

June 8, 2026

Press Release

London-Based Life Sciences Litigator Jin Ooi Bolsters Finnegan’s Global IP Litigation Capabilities

June 8, 2026

Award/Ranking

Finnegan Partner Antje Brambrink Shortlisted for Women in Business Law EMEA Award

May 13, 2026

Commentary

Justices to Side with Generic Drugmakers in Patent Spat, Attorneys Predict

May 5, 2026

Award/Ranking

Finnegan Wins IP Firm of the Year at the 2026 LSPN Awards

May 1, 2026

More

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP